A Phase 1 interventional study of Zavegepant 100mg non-enteric coated soft gel capsule and Zavegepant 100mg immediate release tablet in Biological Availability, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial is designed to compare the rate and extent of absorption of four different formulations of zavegepant. 52 healthy male and female volunteers will receive a single dose of each formulation at least 7 days apart over a period of about 7 weeks and the amount of drug in their blood will be assessed over the 24 hour period after each dose.
This is a Phase 1, single centre, open-label, single dose, 4-period, crossover study designed to compare the pharmacokinetics (PK) of zavegepant from three Test products and a Reference product (treatment D).
52 male and female healthy volunteers will be randomly assigned to one of 4 treatment sequences: ACBD, CDAB, BADC, and DBCA.
In each period, subjects will receive one of the following: Treatment A, B, C, or D on Day 1, followed by 24 hours of PK and safety assessments. On Day 2 subjects will be discharged from the clinical site and instructed to return after at least a 7 day washout time has passed for subsequent periods of treatment.
The study will include a screening visit from Day -28 to Day -2. Eligible subjects will be admitted to the clinical site on Day -1 and will be confined until completion of the assessments on Day 2. There will be a washout period of at least 7 days between doses. Study Exit procedures will be performed after the last assessment on the morning of Day 2 of Period 4. Study Exit procedures will be performed as soon as possible in case of Early Termination.
The total duration of study participation for each subject from Screening through Study Exit is anticipated to be approximately 6.5 weeks.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 2 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 3 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 4 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D).
Drug: Zavegepant 100mg non-enteric coated soft gel capsule · Drug: Zavegepant 100mg immediate release tablet · Drug: Zavegepant 2 x 100mg immediate release tablets · Drug: Zavegepant 4 x 25mg enteric coated soft gel capsule
Period 1 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 2 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 3 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 4 - Single zavegepant 100mg immediate release tablet (Treatment B).
Drug: Zavegepant 100mg non-enteric coated soft gel capsule · Drug: Zavegepant 100mg immediate release tablet · Drug: Zavegepant 2 x 100mg immediate release tablets · Drug: Zavegepant 4 x 25mg enteric coated soft gel capsule
Period 1 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 2 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 3 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 4 - Two zavegepant 100mg immediate release tablets (Treatment C).
Drug: Zavegepant 100mg non-enteric coated soft gel capsule · Drug: Zavegepant 100mg immediate release tablet · Drug: Zavegepant 2 x 100mg immediate release tablets · Drug: Zavegepant 4 x 25mg enteric coated soft gel capsule
Period 1 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 2 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 3 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 4 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A).
Drug: Zavegepant 100mg non-enteric coated soft gel capsule · Drug: Zavegepant 100mg immediate release tablet · Drug: Zavegepant 2 x 100mg immediate release tablets · Drug: Zavegepant 4 x 25mg enteric coated soft gel capsule
Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule
Also known as: Treatment A
Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet
Also known as: Treatment B
2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg
Also known as: Treatment C
Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg
Also known as: Treatment D
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Zavegepant
AUCinf was calculated as AUClast+(Clast\*/kel), where AUClast is the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AUClast was calculated using Linear/Log trapezoidal method.
Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose
Maximum Observed Concentration (Cmax) of Zavegepant
Cmax was observed directly from data.
Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose
AUClast of Zavegepant
AUClast was calculated using linear/log trapezoidal method.
Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose
Time to Reach Cmax (Tmax) of Zavegepant
Tmax was observed directly from data as time of first occurrence.
Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose
Terminal Phase Half-Life (t1/2) of Zavegepant
t1/2 was calculated as Log e(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose
Apparent Clearance (CL/F) of Zavegepant From Plasma
CL/F was calculated as dose/AUCinf. AUCinf was calucalted as AUClast+(Clast\*/kel), where Clast\* is the predicted plasma concentration at the last quantifiable time point estimated, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AUClast was calculated using linear/log trapezoidal method.
Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose
Apparent Volume of Distribution (Vz/F) of Zavegepant
Vz/F was calculated by Dose/(AUCinf×kel). AUCinf was calculated by AUClast+(Clast\*/kel), where Clast\* is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AUClast was calculated using the linear/log trapezoidal method.
Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Adverse evetn (AE)=any untoward medical occurrence in a patient or clinical trial participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. TEAEs=AEs between first dose of study treatment and up to the end of study participation that were absent before treatment or that worsened relative to pretreatment state. A serious TEAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were adjudicated according to the investigator's assessment. Treatment-related was classified based on medical judgement. Severe=Incapacitating with inability to carry out usual activities or significantly affects clinical status, and requires specific action and/or medical attention.
Time frame: Baseline up to study exit (approximately 6.5 weeks)
Number of Participants With Clinically Significant Laboratory Abnormalities
Clinically significant laboratory abnormalities were identified as Grade 3 to 4 laboratory test results graded according to numeric laboratory test criteria in the latest version of Common Technical Criteria for Adverse Events (CTCAE) if available, otherwise according to the latest version of Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version. Clinically significant laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last results (scheduled or unscheduled) obtained prior to the first drug administration.
Time frame: Baseline up to study exit (approximately 6.5 weeks)
Blood Pressure on Day -1 and Day 1 of Each Period
Blood pressure was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for systolic blood pressure (SBP)=90-140 mm Hg; normal range for diastolic blood pressure (DBP)=50-90 mm Hg.
Time frame: Day -1, pre-dose and 2 hours post dose on Day 1 of each period
Blood Pressure at Screening and Study Exit
Blood pressure was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for SBP=90-140 mm Hg; normal range for DBP=50-90 mm Hg.
Time frame: Screening and study exit
Heart Rate (HR) on Day -1 and Day 1 of Each Period
HR was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for heart rate=50-100 beats/min.
Time frame: Day -1, pre-dose and 2 hours post dose on Day 1 of each period
HR at Screening and Study Exit
HR was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for heart rate=50-100 beats/min.
Time frame: Screening and study exit
Respiratory Rate (RR) on Day -1 of Each Period
RR was measured after the participants had been resting for at least 5 minutes in a sitting position. Normal range for RR=8-20 breaths/min.
Time frame: Day -1 of each period
RR at Screening and Study Exit
RR was measured after the participants had been resting for at least 5 minutes in a sitting position. Normal range for RR=8-20 breaths/min.
Time frame: Screening and study exit
Temperature on Day -1 of Each Period
Temperature was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for temperature=35.8-37.6 ℃.
Time frame: Day -1 of each period
Temperature at Screening and Study Exit
Temperature was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for temperature=35.8-37.6 ℃.
Time frame: Screening and study exit
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG)
ECG was measured after the participants had been resting for at least 5 minutes in a seated position.
Time frame: Screening up to study exit (approximately 6.5 weeks)
| Milestone | Sequence DBCA | Sequence BADC | Sequence ACBD | Sequence CDAB |
|---|---|---|---|---|
| Started | 13 | 13 | 13 | 13 |
| Completed | 13 | 12 | 12 | 13 |
| Not completed | 0 | 1 | 1 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
AUCinf was calculated as AUClast+(Clast\*/kel), where AUClast is the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AUClast was calculated using Linear/Log trapezoidal method.
| Hours*nanograms per milliliter (h*ng/mL) | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Zavegepant | 83.65 ± 52 | 102.5 ± 66 | 184.4 ± 73 | 47.29 ± 51 |
Cmax was observed directly from data.
| ng/mL | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) of Zavegepant | 36.28 ± 68 | 41.20 ± 80 | 76.93 ± 77 | 12.78 ± 82 |
AUClast was calculated using linear/log trapezoidal method.
| h*ng/mL | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| AUClast of Zavegepant | 82.13 ± 54 | 96.25 ± 66 | 175.5 ± 72 | 42.25 ± 54 |
Tmax was observed directly from data as time of first occurrence.
| Hours | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| Time to Reach Cmax (Tmax) of Zavegepant | 0.9830 (0.483 to 3.00) | 0.5000 (0.250 to 2.62) | 0.5000 (0.233 to 2.48) | 2.000 (0.483 to 5.00) |
t1/2 was calculated as Log e(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| Hours | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| Terminal Phase Half-Life (t1/2) of Zavegepant | 8.346 ± 1.3101 | 8.907 ± 2.3611 | 8.243 ± 1.3004 | 9.149 ± 1.5552 |
CL/F was calculated as dose/AUCinf. AUCinf was calucalted as AUClast+(Clast\*/kel), where Clast\* is the predicted plasma concentration at the last quantifiable time point estimated, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AUClast was calculated using linear/log trapezoidal method.
| liters per hour (L/h) | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| Apparent Clearance (CL/F) of Zavegepant From Plasma | 1195 ± 52 | 975.5 ± 66 | 1085 ± 73 | 2115 ± 51 |
Vz/F was calculated by Dose/(AUCinf×kel). AUCinf was calculated by AUClast+(Clast\*/kel), where Clast\* is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AUClast was calculated using the linear/log trapezoidal method.
| L | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Zavegepant | 14230 ± 60 | 12250 ± 79 | 12740 ± 85 | 27530 ± 59 |
Adverse evetn (AE)=any untoward medical occurrence in a patient or clinical trial participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. TEAEs=AEs between first dose of study treatment and up to the end of study participation that were absent before treatment or that worsened relative to pretreatment state. A serious TEAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were adjudicated according to the investigator's assessment. Treatment-related was classified based on medical judgement. Severe=Incapacitating with inability to carry out usual activities or significantly affects clinical status, and requires specific action and/or medical attention.
| Participants | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| Participants with at least 1 TEAE | 3 | 2 | 4 | 3 |
| Participants with at least 1 treatment-related TEAE | 1 | 0 | 1 | 0 |
| Participants with at least 1 Severe TEAEs | 1 | 0 | 0 | 1 |
| Participants with at least 1 Serious TEAEs | 1 | 0 | 0 | 0 |
Clinically significant laboratory abnormalities were identified as Grade 3 to 4 laboratory test results graded according to numeric laboratory test criteria in the latest version of Common Technical Criteria for Adverse Events (CTCAE) if available, otherwise according to the latest version of Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version. Clinically significant laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last results (scheduled or unscheduled) obtained prior to the first drug administration.
| Participants | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| Hematology - Hemoglobin<lower limit of normal | 1 | 0 | 1 | 0 |
| Urinalysis - Abnormal Leukocyte Esterase | 0 | 0 | 0 | 1 |
| Urinalysis - Abnormal Urine Leukocytes | 0 | 0 | 0 | 1 |
Blood pressure was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for systolic blood pressure (SBP)=90-140 mm Hg; normal range for diastolic blood pressure (DBP)=50-90 mm Hg.
| millimeter of mercury (mm Hg) | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| SBP on Day -1 | 115.0 (99 to 137) | 115.0 (99 to 140) | 116.5 (94 to 140) | 116.5 (97 to 138) |
| Pre-dose SBP on Day 1 of each period | 113.0 (74 to 132) | 113.0 (93 to 132) | 114.0 (92 to 144) | 114.5 (94 to 138) |
| SBP at 2 hours post dose on Day 1 of each period | 113.0 (94 to 150) | 114.0 (94 to 135) | 113.5 (91 to 144) | 113.0 (92 to 137) |
| DBP at Day -1 | 75.0 (62 to 90) | 77.0 (59 to 89) | 76.0 (64 to 92) | 76.0 (60 to 92) |
| Pre-dose DBP on Day 1 of each period | 75.0 (52 to 92) | 76.0 (63 to 90) | 74.0 (64 to 89) | 76.0 (63 to 90) |
| DBP at 2 hours post dose on Day 1 of each period | 75.0 (57 to 100) | 76.0 (62 to 97) | 77.0 (61 to 91) | 75.0 (66 to 88) |
Blood pressure was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for SBP=90-140 mm Hg; normal range for DBP=50-90 mm Hg.
| mm Hg | All Participants |
|---|---|
| SBP at Screening | 121.5 (102 to 144) |
| SBP at study exit | 114.0 (94 to 137) |
| DBP at Screening | 82.0 (65 to 91) |
| DBP at study exit | 76.0 (63 to 90) |
HR was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for heart rate=50-100 beats/min.
| Beats per minute (beats/min) | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| HR on Day -1 | 71.0 (50 to 102) | 72.0 (49 to 102) | 73.0 (50 to 99) | 73.0 (56 to 100) |
| Pre-dose HR on Day 1 of each period | 73.0 (51 to 93) | 74.0 (47 to 99) | 73.5 (52 to 103) | 73.5 (51 to 110) |
| HR at 2 hours post dose on Day 1 of each period | 71.0 (51 to 97) | 70.0 (48 to 90) | 71.0 (48 to 108) | 70.0 (50 to 99) |
HR was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for heart rate=50-100 beats/min.
| beats/min | All Participants |
|---|---|
| HR at Screening | 65.0 (46 to 93) |
| HR at study exit | 74.0 (53 to 100) |
RR was measured after the participants had been resting for at least 5 minutes in a sitting position. Normal range for RR=8-20 breaths/min.
| Breaths per minute (breaths/min) | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| Respiratory Rate (RR) on Day -1 of Each Period | 14.0 (12 to 18) | 14.0 (12 to 16) | 14.0 (12 to 18) | 14.0 (12 to 18) |
RR was measured after the participants had been resting for at least 5 minutes in a sitting position. Normal range for RR=8-20 breaths/min.
| breaths/min | All Participants |
|---|---|
| RR at Screening | 14.0 (12 to 16) |
| RR at study exit | 14.0 (12 to 18) |
Temperature was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for temperature=35.8-37.6 ℃.
| Degree Celsius (℃) | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| Temperature on Day -1 of Each Period | 36.60 (36.1 to 37.6) | 36.40 (35.9 to 37.0) | 36.50 (35.9 to 37.2) | 36.50 (36.1 to 37.4) |
Temperature was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for temperature=35.8-37.6 ℃.
| ℃ | All Participants |
|---|---|
| Temperature at Screening | 36.40 (35.9 to 36.8) |
| Temperature at study exit | 36.60 (35.8 to 37.4) |
ECG was measured after the participants had been resting for at least 5 minutes in a seated position.
| Participants | All Participants |
|---|---|
| ECG Mean Heart Rate | 0 |
| PR Interval, Aggregate | 0 |
| QRS Duration, Aggregate | 0 |
| QT Interval, Aggregate | 0 |
| QTc corrected using Bazett's formula (QTcB) Interval, Aggregate | 0 |
| QTc corrected using Fridericia's formula (QTcF) Interval, Aggregate | 0 |
Collected over Screening up to study exit (approximately 6.5 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: Zavegepant 100 mg SGC | 0/51 (0%) | 1/51 (2%) | 3/51 (5.9%) |
| Treatment B: Zavegepant 100 mg IR+DDM | 0/51 (0%) | 0/51 (0%) | 2/51 (3.9%) |
| Treatment C: Zavegepant 200 mg IR+DDM | 0/50 (0%) | 0/50 (0%) | 4/50 (8%) |
| Treatment D: Zavegepant 4*25 mg SGC | 0/50 (0%) | 0/50 (0%) | 3/50 (6%) |
| Event | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 1/51 | 0/51 | 0/50 | 0/50 |
| Pancreatitis acuteGastrointestinal disorders | 1/51 | 0/51 | 0/50 | 0/50 |
| Event | Treatment A: Zavegepant 100 mg SGC | Treatment B: Zavegepant 100 mg IR+DDM | Treatment C: Zavegepant 200 mg IR+DDM | Treatment D: Zavegepant 4*25 mg SGC |
|---|---|---|---|---|
| Skin abrasionInjury, poisoning and procedural complications | 1/51 | 0/51 | 2/50 | 1/50 |
| Haemoglobin decreasedInvestigations | 0/51 | 1/51 | 0/50 | 1/50 |
| DizzinessNervous system disorders | 0/51 | 1/51 | 1/50 | 1/50 |
| SyncopeNervous system disorders | 0/51 | 0/51 | 0/50 | 1/50 |
| NauseaGastrointestinal disorders | 0/51 | 0/51 | 1/50 | 0/50 |
| Alanine aminotransferase increasedInvestigations | 1/51 | 0/51 | 0/50 | 0/50 |
| Aspartate aminotransferase increasedInvestigations | 1/51 | 0/51 | 0/50 | 0/50 |
| Blood bilirubin increasedInvestigations | 1/51 | 0/51 | 0/50 | 0/50 |
| Lipase increasedInvestigations | 1/51 | 0/51 | 0/50 | 0/50 |
| White blood cells urine positiveInvestigations | 1/51 | 0/51 | 0/50 | 0/50 |
Included all participants who received at least 1 dose of any study intervention.
| Age, Customized(Years) | All Participants |
|---|---|
| 18-65 years of age | 37.0 (22 to 48) |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 19 |
| Male | 33 |
| Race/Ethnicity, Customized(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 51 |
| Not Hispanic or Latino | 1 |
| Not Reported | 0 |
| Unknown | 0 |
| Race/Ethnicity, Customized(Participants) | All Participants |
|---|---|
| American Indian | 0 |
| Asian | 0 |
| Black | 11 |
| Hawaiian | 0 |
| White | 41 |
| Multiple | 0 |
| Other | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Aug 2022 to primary completion in Dec 2022, 3 months.
Results were first posted in Oct 2024, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zavegepant